CClinicalTrials.gg
Status unknownNCT05178953PTX-ZnUpdated Jan 5, 2022

The Therapeutic Effect of Co-administration of Pentoxifylline and Zinc in Men With Idiopathic Asthenozoospermia

An Early Phase 1 interventional study of Zinc Sulfate 220 mg Capsules and Pentoxifylline in Men Infertility, sponsored by Arak University of Medical Sciences. Status unknown at 2 sites in Iran, Islamic Republic of. Open to male participants aged 23 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-05.

Sponsored by Arak University of Medical Sciences · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Early Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
23 Years to 45 Years
Sex
Male
01

Study summary

The aim of this study was to investigate the therapeutic effect of co-administration of pentoxifylline and zinc on sperm apoptosis in men with idiopathic infertility

Read the detailed description

This study is being performed as a double-blind randomized clinical trial on idiopathic infertile men referred to the infertility clinic of Shafa Clinic. Patient satisfaction, non-use of contraceptives, men aged 25 to 43 years, and idiopathic infertility according to WHO criteria (World Health, 2010) are our study criteria. Any medication that may affect the course of spermatogenesis should be discontinued during the study. Semen samples are taken from patients (before and after interventions) and apoptosis tests are performed on semen samples.

02

Conditions studied

  • Men Infertility

Browse trials for

03

Who can participate

Ages eligible
23 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • infertile men
  • have had at least one year of unprotected intercourse infertility
  • asthenozoospermia

Exclusion criteria

Exclusion Criteria:

  • Men with varicocele
  • Hypersensitivity to pentoxifylline \& zinc,
  • pelvic organic pathologies
  • congenital adrenal hyperplasia
  • thyroid dysfunction
  • Cushing's syndrome
  • hyper prolactinemia
  • androgen secreting neoplasia
  • severe hepatic
  • pancreatitis
  • kidney diseases
  • gallbladder diseases
  • Patients with alcohol consumption
  • Patients who use cigarettes and drugs
04

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    pentoxifylline group

    Group 1: Patients receiving pentoxifylline (TRENTAL 400 mg tablets, OSPS; 400 mg, twice daily) Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. These volunteers receive two pentoxifylline tablets(400 mg) daily for 3 month, (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily) Other names: Trental

    Drug: Pentoxifylline

  • Experimental
    Zinc Sulfate group

    Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate tablet(229 mg) daily for 3 month,(Zinc Sulfate 220mg Capsules) Other Names: zinc sulfate

    Drug: Zinc Sulfate 220 mg Capsules

  • Experimental
    pentoxifylline+ zinc group

    Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules) Other Names: zinc sulfate

    Drug: Zinc Sulfate 220 mg Capsules · Drug: Pentoxifylline

Interventions

  • DrugZinc Sulfate 220 mg Capsules

    Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months

    Also known as: zinc

  • DrugPentoxifylline

    Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months

    Also known as: Trental

05

What researchers measure

Primary outcomes

  1. sperm concentration

    count of sperm(In per million - with the help of a neobar slide and microscopic observation

    Time frame: 1 day

  2. spem motility

    motility of sperm: Calculate the percentage of motile sperm using microscopic observation

    Time frame: 1 day

  3. sperm morphology

    Calculate the percentage of sperm with a normal shape with the help of Papanic staining

    Time frame: 1 day

  4. lipid proxidation

    Malondialdehyde (nmol/mL), is measured using related experimental kits

    Time frame: One week

  5. reactive oxygen species

    eactive oxygen species (ROS (RLU/s)), is measured using related experimental kits

    Time frame: One week

  6. total antioxidant capacity

    total antioxidant capacity (TAC (/m / l)) is measured using related experimental kits

    Time frame: One week

  7. FSH hormon

    FSH (IU / L) is measured from the blood serum of volunteers using ELISA kit

    Time frame: One week

  8. LH hormon

    LH (IU / L) is measured from the blood serum of volunteers using ELISA kit

    Time frame: One week

  9. testosteron hormon [ Time Frame: One week after starting the medication ] testosterone

    testosterone (nanomolar per liter) is measured from the blood serum of volunteers using ELISA kit

    Time frame: One week

  10. (Tissue necrosis Factor)

    TNF α( Tissue necrosis Factor) (pg/mL) as an inflammatory factor is measured using related experimental kit

    Time frame: One week

  11. interleukin-6

    interleukin-6 (IL-6)/(pg/mL) as an inflammatory factor is measured using related experimental kit

    Time frame: One week

  12. Sperm DNA Fragmentation Assay(SDFA)

    DNA fragmentation is assessed using an SDFA kit and microscopic observations (as a percentage of damaged sperm).

    Time frame: One week

Secondary outcomes

  1. BAX expression

    BAX expression \[ Time Frame: 3 months \] expression of BAX gen(in p.c) using real-time PCR and Western blot

    Time frame: 3 month

  2. Bcl2 expression

    Bcl-2 gen(in p.c) using real-time PCR and Western blot

    Time frame: 3 months

  3. caspase 3 expression

    expression of caspase 3 gen(in p.c) using real-time PCR and Western blot

    Time frame: 3 months

06

Study locations

1 of 2 sites recruiting
  • Infertility Center
    Arak, Markazi 6853462355, Iran, Islamic Republic of
    Recruiting
  • Arak university of medical science
    Arak, Markazi 68985432, Iran, Islamic Republic of
    Completed
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05178953
Lead sponsor
Arak University of Medical Sciences
Responsible party
Zeynab (Principal Investigator, Arak University of Medical Sciences) — Principal investigator
First posted
Jan 5, 2022
Start date
Aug 1, 2021
Primary completion
Jan 8, 2022 (estimated)
Completion
Jan 20, 2022 (estimated)
Last update
Jan 5, 2022

Study contacts

zeynab dadgar, dr
Contact
z.dadgar67@gmail.com
09163619937 ext. arak
hamzeh amiri, dr
Contact
h.amiri65@gmail.com
09163631770 ext. shafa
zeynab dadgar, dr
principal investigator · arak university of medical science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion